
Annual report 2025
added 02-24-2026
AdaptHealth Corp. Net Debt 2011-2026 | AHCO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt AdaptHealth Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.64 B | 1.89 B | 2.05 B | 2.14 B | 2.07 B | 685 M | 320 M | -947 K | 54.4 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.14 B | -947 K | 1.2 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Alphatec Holdings
ATEC
|
347 M | $ 13.93 | 5.85 % | $ 2.09 B | ||
|
AxoGen
AXGN
|
15.2 M | $ 32.5 | -8.14 % | $ 1.5 B | ||
|
Bio-Rad Laboratories
BIO
|
754 M | $ 268.7 | 0.17 % | $ 7.58 B | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Aziyo Biologics
AZYO
|
1.36 M | - | 1.37 % | $ 20.5 M | ||
|
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 6.39 | 0.79 % | $ 459 M | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.54 | -0.84 % | $ 123 M | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
-16.5 M | $ 14.55 | -1.42 % | $ 393 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 4.47 | -1.11 % | $ 167 M | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 39.77 | 0.53 % | $ 5.93 K | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
9.26 B | $ 75.15 | 1.05 % | $ 111 B | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
-10.5 M | $ 23.15 | -5.16 % | $ 196 M | ||
|
CONMED Corporation
CNMD
|
802 M | $ 46.06 | 1.5 % | $ 1.43 B | ||
|
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
IRadimed Corporation
IRMD
|
-52.1 M | $ 99.09 | -1.92 % | $ 1.26 B | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
-2.46 M | $ 9.95 | 2.16 % | $ 284 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
LivaNova PLC
LIVN
|
130 M | $ 69.05 | 1.02 % | $ 3.75 B | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
InMode Ltd.
INMD
|
-34.8 M | $ 13.98 | -1.55 % | $ 904 M | ||
|
Pulmonx Corporation
LUNG
|
-36.1 M | $ 1.51 | 2.03 % | $ 59.1 M | ||
|
Establishment Labs Holdings
ESTA
|
131 M | $ 79.67 | 6.28 % | $ 2.24 B | ||
|
Myomo
MYO
|
-4.79 M | $ 0.65 | -5.24 % | $ 4.58 M | ||
|
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | ||
|
Orthofix Medical
OFIX
|
78.5 M | $ 12.75 | -6.18 % | $ 505 M | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.57 | -0.11 % | $ 122 M | ||
|
Insulet Corporation
PODD
|
468 M | $ 245.25 | -1.66 % | $ 17.3 B | ||
|
Globus Medical
GMED
|
-511 M | $ 91.88 | -1.63 % | $ 12.4 B |